News-Medical.netRocket Pharma partners with Stanford University to advance FA and PKD gene therapy researchNews-Medical.netRocket Pharmaceuticals, Inc. ("Rocket"), a leading U.S.-based multi-platform gene therapy company, and the Stanford Uni… Continue reading
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT MeetingGlobeNewswire (press release)NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage b… Continue reading
Synthetic Biology Market – United States Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2025Exclusive ReportageThe United States Synthetic Biology Market report takes into account the production data, consumption data, and revenue … Continue reading
Synthetic Biology Market – United States Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2025Exclusive ReportageThe United States Synthetic Biology Market report takes into account the production data, consumption data, and revenue … Continue reading
MarketWatch |
Can gene therapy make you super-strong like Jessica Jones? Yes — but it’s complicated
MarketWatch Gene therapy, that very procedure, is already being used to treat complex diseases, with hopes of using it far more widely. Human capabilities could likely be enhanced through gene therapy, possibly attaining even some of the abilities pictured on the … |
PR Newswire (press release) |
USRM Chief Scientist Talks Stem Cell Journey, Autologous Stem Cells with ‘Something Significant’ Happy Living Podcast
PR Newswire (press release) SUNRISE, Fla., May 17, 2018 /PRNewswire/ — U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr … |
|
Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for …
Nasdaq Previously reported data from a Phase 1b clinical trial demonstrated that Inovio’s cancer immunotherapy (INO-5150) slowed PSA rise in patients with biochemically recurrent prostate cancer. Additional analyses show clinically meaningful PSA … |
|
Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for …
GlobeNewswire (press release) Previously reported data from a Phase 1b clinical trial demonstrated that Inovio’s cancer immunotherapy (INO-5150) slowed PSA rise in patients with biochemically recurrent prostate cancer. Additional analyses show clinically meaningful PSA … |